Anzeige
Mehr »
Donnerstag, 12.03.2026 - Börsentäglich über 12.000 News
Dieser 37-Mio.-€-Goldentwickler sitzt auf einem möglichen $2-Milliarden-Projekt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W5SA | ISIN: US9224751084 | Ticker-Symbol: VEE
Tradegate
12.03.26 | 17:04
161,50 Euro
-0,19 % -0,30
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
VEEVA SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
VEEVA SYSTEMS INC 5-Tage-Chart
RealtimeGeldBriefZeit
158,55158,9020:35
158,45159,0020:35
PR Newswire
1.311 Leser
Artikel bewerten:
(2)

Veeva Systems: 13 of the Top 20 Biopharmas Standardize Globally on Veeva Link Key People

Emerging biotechs and top biopharmas trust Link to power customer engagement and provide structured datasets to fuel AI initiatives

BARCELONA, Spain, Feb. 4, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 13 of the top 20 biopharmas have standardized on Veeva Link Key People to enhance customer engagement and provide data for AI globally. Biopharmas of all sizes use Link Key People, with 38 new customers added and three of the top 20 biopharmas making it their global standard within the last year.

Veeva Systems

"Access to Veeva Link Key People further strengthens data-driven decision-making, enhances laser-sharp targeting, and fosters more engaging HCP interactions - altogether benefiting patient healthcare. As ingested, Link Key People data has become an organic part of Bayer's Data DNA, it enriches the outputs of our agentic, AI-driven platforms, delivering more relevant and actionable business insights for the long-term benefit of patients," said Dr. Daniel Jardanhazi-Kurutz, deputy director for customer engagement at Bayer AG.

Link Key People delivers value to medical and commercial teams by providing trusted insights, while analytics teams can use Link data to feed their AI models. Recent innovations, such as AI-powered summaries, personalized notifications, and new digital data sources, further improve customer interactions and help to uncover new engagement opportunities. Additionally, the Link Direct Data API gives data teams access to Veeva's new class of API that provides high-speed access to data.

"Trusted customer insights are the foundation for AI advancement and help achieve launch performance. With more top biopharmas and emerging biotechs using Link Key People, we will continue to learn and advance engagement across the industry with deep KOL data for strategic and impactful relationships," said David Medina Tato, vice president of strategy for Link Key People at Veeva.

Link Key People is part of Veeva Data Cloud, which includes Veeva OpenData, Veeva HCP 360, and Veeva Compass, and Link Key People uses Veeva's Common Data Architecture (CDA) to connect data and software.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:
Meera Lakhani-Patel
Veeva Systems
+44-790-430-0698
meera.lakhani-patel@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo_v2.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/13-of-the-top-20-biopharmas-standardize-globally-on-veeva-link-key-people-302678421.html

© 2026 PR Newswire
Tech-Aktien schwanken – 3 Versorger mit Rückenwind
Die Stimmung an den Märkten hat sich grundlegend gedreht. Während Tech- und KI-Werte zunehmend mit Volatilität und Bewertungsrisiken kämpfen, erleben klassische Versorger ein unerwartetes Comeback. Laut IEA und EIA steigt der globale Strombedarf strukturell weiter, nicht nur wegen E-Mobilität und Wärmepumpen, sondern vor allem durch energiehungrige KI-Rechenzentren. Energie wird damit zur zentralen Infrastruktur des digitalen Zeitalters.

Gleichzeitig rücken in unsicheren Marktphasen stabile Cashflows, solide Bilanzen und regulierte Renditen wieder stärker in den Fokus. Genau hier spielen Versorger ihre Stärken aus: berechenbare Erträge, robuste Nachfrage und hohe Dividenden – Qualitäten, die vielen Wachstumswerten aktuell fehlen.

Nach Jahren im Schatten der Tech-Rallye steigt nun das Interesse an Unternehmen, die Stabilität mit langfristigen Wachstumsthemen wie Netzausbau, Dekarbonisierung und erneuerbaren Energien verbinden.

Im aktuellen Spezialreport stellen wir drei Versorger vor, die defensive Stärke mit attraktivem Potenzial kombinieren.

Jetzt den kostenlosen Report sichern – bevor die nächste Versorgerwelle Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.